The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Open accessAbstract
Summary The transition from castration resistant prostate adenocarcinoma (CRPC) to neuroendocrine prostate cancer (NEPC) has emerged as an important mechanism of treatment resistance. NEPC is associated with over-expression and gene amplification of MYCN (encoding N-Myc). N-Myc is an established oncogene in several rare pediatric tumors, but its role in prostate cancer progression is not well established. Integrating a genetically engineered mouse model and human prostate cancer transcriptome data, we show that N-Myc over-expression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC. This includes an abrogation of AR signaling and induction of Polycomb Repressive Complex 2 signaling. Altogether, our data establishes N-Myc as an oncogenic driver of NEPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationThe Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citationDivergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationCarver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Self-citationMolecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0130 · Cited by 999
Self-citationEZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
Karthaus, W. R., Iaquinta, P. J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., Dowling, C. M., Gao, D., Begthel, H., Sachs, N., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.017 · Cited by 727
Self-citation
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
Self-citationThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, Á., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 572
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Beltran, H., Hruszkewycz, A., Scher, H. I., Hildesheim, J., Isaacs, J., Yu, E. Y., Kelly, K., Lin, D., Dicker, A., Arnold, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1423 · Cited by 405
Self-citationZou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 386
Self-citationPatient derived organoids to model rare prostate cancer phenotypes
Puca, L., Bareja, R., Prandi, D., Shaw, R., Benelli, M., Karthaus, W. R., Hess, J., Sigouros, M., Donoghue, A., Kossai, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04495-z · Cited by 361
Self-citationPolycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
Kim, J., Lee, Y., Lu, X., Song, B., Fong, K.-W., Cao, Q., Licht, J. D., Zhao, J. C., & Yu, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.035 · Cited by 306
Clinical and Biological Features of Neuroendocrine Prostate Cancer
Yamada, Y., & Beltran, H. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01003-9 · Cited by 305
Self-citationBhat, G. R., Sethi, I., Sadida, H. Q., Rah, B., Mir, R., Algehainy, N., Albalawi, I. A., Masoodi, T., Subbaraj, G. K., Jamal, F., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10172-z · Cited by 281
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer
Han, M., Li, F., Zhang, Y., Dai, P., He, J., Li, Y., Zhu, Y., Zheng, J., Huang, H., Bai, F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.011 · Cited by 166
Self-citationBiological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
Self-citationTrop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
Hsu, E.-C., Rice, M. A., Bermudez, A., Marques, F. J. G., Aslan, M., Liu, S., Ghoochani, A., Zhang, C. A., Chen, Y.-S., Zlitni, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905384117 · Cited by 146
Self-citationKarnes, R. J., Sharma, V., Choeurng, V., Ashab, H. A.-D., Erho, N., Alshalalfa, M., Trock, B., Ross, A., Yousefi, K., Tsai, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2745 · Cited by 30
Ton, A.-T., Foo, J., Singh, K., Lee, J., Kalyta, A., Morin, H., Perez, C., Ban, F., Leblanc, E., Lallous, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052588 · Cited by 17
“Given the high structural and functional similarity between the c-Myc and N-Myc oncoproteins [19,20], we used our previously-developed chemical series targeting MycMax/DBD complex as templates for the further development of novel N-Myc specific inhibitors [21,22].”
Method
Metadata
- Authors
- Dardenne, E., Beltran, H., Benelli, M., Gayvert, K., Berger, A., Puca, L., Cyrta, J., Sboner, A., Noorzad, Z., MacDonald, T., Cheung, C., Yuen, K. S., Gao, D., Chen, Y., Eilers, M., Mosquera, J.-M., Robinson, B. D., Elemento, O., Rubin, M. A., Demichelis, F., & Rickman, D. S.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 30
- Issue
- 4
- Pages
- 563-577
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2530065228
- Cited by
- 559
- References
- 45
- FWCI
- 34.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.